Oncternal Therapeutics, Inc. Announces Board Changes
December 23, 2019 at 04:37 pm IST
Share
Oncternal Therapeutics, Inc. announced that on December 18, 2019, Dr. Yanjun Liu notified the Company that he was resigning from the Company's board of directors, effective immediately. Dr. Liu's resignation did not result from any disagreement with the Company on any matter relating to its operations, policies or practices. Effective December 18, 2019, upon the recommendation of the nominating and corporate governance committee, and pursuant to the Company's bylaws, the board of directors appointed Man Cho as a Class II director of the Company effective as of the date of Mr. Liu's resignation, with an initial term expiring at the 2021 annual meeting of the stockholders of the Company, to fill the vacancy left by Dr. Liu. Mr. Cho, 58, has served since 2013 as Executive Director and President of Shanghai Pharmaceuticals Holding Co. Ltd. (Shanghai Pharmaceuticals). Prior to his role at Shanghai Pharmaceuticals, Mr. Cho was Vice Chairman and Chief Executive Officer of Wing Fat Printing Co. Ltd. From 2008 to 2013. Mr. Cho has also served as Vice President of China Resources Pharmaceutical Group, Vice Director and head of the sales department of Shenzhen South Pharmaceutical Co. Ltd. and head of the transfusion medicine department, head of the drug injection department and pharmacist at Nanfang Hospital.
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Companyâs product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.